KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (5y) (2021 - 2025)
KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (5y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 67.49% |
| Apr 30, 2025 | 84.92% |
| Oct 31, 2024 | -10.63% |
| Jul 31, 2024 | -8.17% |
| Apr 30, 2024 | -23.87% |
| Jan 31, 2024 | 70.24% |
| Oct 31, 2023 | -60.98% |
| Jul 31, 2023 | -59.71% |
| Apr 30, 2023 | -42.35% |
| Jan 31, 2023 | -39.30% |
| Oct 31, 2022 | 30.36% |
| Jul 31, 2022 | 52.93% |
| Apr 30, 2022 | 65.15% |
| Jan 31, 2022 | 102.04% |
| Oct 31, 2021 | 81.65% |
| Jul 31, 2021 | 46.18% |